




RealRate

PHARMACEUTICAL 2022

Inmed Pharmaceuticals Inc
Rank 312 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Inmed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Inmed Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Inmed Pharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 45% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	8,378
Cost of Goods Sold	0
Intangible Assets	1,062
Liabilities, Current	2,215
Liabilities, Non-Current	189
Other Assets	341
Other Compr. Net Income	430
Other Expenses	121
Other Liabilities	0
Other Net Income	-265
Other Revenues	0
Property and Equipment	0
Research and Development	5,338
Selling, General and Administrative Expense	4,479

Output Variable	Value in 1000 USD
Assets	9,781
Liabilities	2,405
Expenses	9,938
Revenues	0
Stockholders Equity	7,377
Net Income	-10,203
Comprehensive Net Income	-9,988
BaseVar	11,410
ECR before Limited Liability	100%
Economic Capital Ratio	230%